DORAL, Florida, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces a distribution agreement to market its Hygee™ medical device in Vietnam, as well as provides an update on its CBD product line.
As ETST nears the completion of its first commercial batch of Hygee™, Queen Concept Inc. for the next five years will be the exclusive distributor of Hygee™ in Vietnam. The distributor will have access to the stock needed for the Vietnamese market.
The World Health Organization (WHO) recommends that all pregnant women be tested for chlamydia in order to avoid serious complications for the mother and the baby. Vietnam records 1.7 million pregnancies each year. It is also recommended that all sexually active women between the ages of 15 and 25 get tested yearly. In Vietnam, roughly 7.5 million women are within this demographic. To learn more, visit: https://www.cdc.gov/std/stats17/chlamydia.htm
“We are ready to export Hygee™ in Asia and the Middle East – starting with Vietnam – which will act as a proving ground for the coming introduction of Hygee™ in the other countries we will target,” said ETST Chairman Nickolas Tabraue. “Our testing protocols are ready to conduct high throughput screening for genital chlamydia anywhere around the world.”
Per the agreement, Queen Concept will also plan and execute a chlamydia prevalence study that will use the device in a targeted cohort of 200 young women at high risk of contracting the sexually transmitted infection. This prelaunch clinical study aims to demonstrate Hygee™’s efficiency and support the establishment of a licensed laboratory in Vietnam to conduct in vitro molecular diagnostics for the device. Initially, laboratory analyses will be done in Montreal, Canada. The technical knowledge will be transferred to the new Vietnamese lab once it is established.
Hygee™’s branding will be protected in Vietnam, and ETST expects that this protection will extend to other countries as it expands its product availability.
New CBD Product Update
ETST is also pleased to announce the upcoming launch of three products, starting with the PropoDiol throat spray announced in December 2018. This new formula was developed as a joint venture with Laboratoire Bionatus Pharmacognosique Inc., the Canadian division of Brazil’s Bionatus Pharmaceutical Laboratory.
Key to the development of this new product was the integration of ETST’s High Grade Full Spectrum Cannabinoids Oil.
In March, ETST will meet with representatives of Bionatus in the Company’s Florida offices to discuss the U.S. launch of PropoDiol, to review of the regulatory compliance, and to plan for future cooperation.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Nickolas S. Tabraue
President, Director & Chairman